Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2.
Manish C ChoudharyRinki DeoTeresa H EveringKara W ChewMark J GigantiCarlee B MoserJustin RitzJames ReganJames P FlynnCharles R CrainDavid Alain WohlJudith S CurrierJoseph J EronDavid MargolisQing ZhuLijie ZhonLi YaAlexander L GreningerMichael D HughesDavey SmithEric S DaarJonathan Z LiPublished in: The Journal of infectious diseases (2024)
Compared with single-active mAb therapy, dual-active mAbs led to similar clinical outcomes but significantly faster viral load decline and a lower risk of emergent resistance.